Literature DB >> 2193628

Double-blind, randomized, controlled clinical trial of norfloxacin for cholera.

S K Bhattacharya1, M K Bhattacharya, P Dutta, D Dutta, S P De, S N Sikdar, A Maitra, A Dutta, S C Pal.   

Abstract

In a double-blind, randomized clinical trial with 78 adults with acute watery diarrhea and severe dehydration, 37 subjects were positive for Vibrio cholerae. In conjunction with rehydration therapy, 13 patients received norfloxacin, 12 received trimethoprim-sulfamethoxazole (TMP-SMX), and 12 received a placebo. Norfloxacin was superior to TMP-SMX and to the placebo in reducing stool output, duration of diarrhea, fluid requirements, and vibrio excretion. TMP-SMX was no better than the placebo.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2193628      PMCID： PMC171728          DOI： 10.1128/AAC.34.5.939

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Effect of chemotherapy on the duration of diarrhoea, and on vibrio excretion by cholera patients.

Authors:  T I Francis; E A Lewis; A B Oyediran; O A Okubadejo; D Montefiore; I I Onyewotu; I Mohammed; E A Ayoola; R Vincent
Journal:  J Trop Med Hyg       Date:  1971-08

2.  Optimal antibiotic therapy in cholera.

Authors:  C K Wallace; P N Anderson; T C Brown; S R Khanra; G W Lewis; N F Pierce; S N Sanyal; G V Segre; R H Waldman
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

3.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

4.  Controlled comparison of tetracycline and furazolidone in cholera.

Authors:  N F Pierce; J G Banwell; R C Mitra; G J Caranasos; R I Keimowitz; J Thomas; A Mondal
Journal:  Br Med J       Date:  1968-08-03

5.  Aetiological studies on hospital in-patients with acute diarrhoea in Calcutta.

Authors:  D Sen; M R Saha; S K Niyogi; G B Nair; S P De; P Datta; D Datta; S C Pal; R Bose; J Roychowdhury
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

6.  In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

7.  In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents.

Authors:  J G Morris; J H Tenney; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191
  7 in total
  8 in total

1.  Therapeutic methods for diarrhea in children.

Authors:  S K Bhattacharya
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

2.  Emergence of fluoroquinolone-resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India.

Authors:  P Garg; S Sinha; R Chakraborty; S K Bhattacharya; G B Nair; T Ramamurthy; Y Takeda
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Emergence of fluoroquinolone resistance in strains of Vibrio cholerae isolated from hospitalized patients with acute diarrhea in Calcutta, India.

Authors:  A K Mukhopadhyay; I Basu; S K Bhattacharya; M K Bhattacharya; G B Nair
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae.

Authors:  Somesh Baranwal; Keya Dey; T Ramamurthy; G Balakrish Nair; Manikuntala Kundu
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 5.  Antimicrobial drugs for treating cholera.

Authors:  Ya'ara Leibovici-Weissman; Ami Neuberger; Roni Bitterman; David Sinclair; Mohammed Abdus Salam; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2014-06-19

Review 6.  Practical guidelines for the treatment of cholera.

Authors:  C Seas; H L DuPont; L M Valdez; E Gotuzzo
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

7.  Comparison between Single Dose Azithromycin and Six Doses, 3 Day Norfloxacin for Treatment of Cholera in Adult.

Authors:  M K Bhattacharya; S Kanungo; T Ramamurthy; K Rajendran; A Sinha; A Bhattacharya; B Sharma Sarkar
Journal:  Int J Biomed Sci       Date:  2014-12

Review 8.  Global status of antimicrobial resistance among environmental isolates of Vibrio cholerae O1/O139: a systematic review and meta-analysis.

Authors:  Xin-Hui Yuan; Yu-Mei Li; Ali Zaman Vaziri; Vahab Hassan Kaviar; Yang Jin; Yu Jin; Abbas Maleki; Nazanin Omidi; Ebrahim Kouhsari
Journal:  Antimicrob Resist Infect Control       Date:  2022-04-25       Impact factor: 6.454
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.